Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEM-102 for Staphylococcal Bone or Joint Infections
NCT02569541Phase 3Completed
- Sponsor
- Arrevus
- Start
- Dec 2015
- Primary completion
- Oct 2017
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of fusidic acid in staphylococcal osteoarticular infection, sponsored by Arrevus. Started Dec 2015; status: completed.
02
Drugs
fusidic acid
03
Conditions
staphylococcal osteoarticular infection
Beyond the preview
Go deeper on NCT02569541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02569541.